Skip to Content

Polymyxin B Sulfate Injection

Last Updated: May 19, 2015
Status: Resolved

Products Affected - Description

Polymyxin B Powder for Solution, West-Ward
500,000 units per vial, 10 count (NDC 55390-0139-10)

Reason for the Shortage

  • Fresenius Kabi could not provide a reason for the shortage.
  • Sagent suspended manufacturing of Polymyxin B sulfate injection in October, 2012.
  • West-Ward Pharmaceuticals’ parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including polymyxin B sulfate injection. West-Ward is not actively marketing polymyxin B sulfate injection.

Available Products

Polymyxin B Powder for Solution, X-Gen

500,000 units per vial, 1 count (NDC 39822-0166-05)
500,000 units per vial, 10 count (NDC 39822-0170-02)
 
Polymyxin B Powder for Solution, Fresenius Kabi
500,000 units per vial, 10 count (NDC 63323-0321-10)

Estimated Resupply Dates

X-Gen and Fresenius Kabi have polymyxin B powder 500,000 unit vials available.

Related Shortages

Updated

May 19, April 14, February 20 and 26, January 28, 2015; November 17, October 17, September 10 and 22, August 28, July 17, 23, and 31, June 5, March 31, January 15, 2014; October 9, September 12, August 15, 22, and 27, June 14, May 8, March 20, January 25, 2013; November 15 and 28, 2012, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide